Updated legislation may boost phytotherapic drug production in Brazil

14 July 2014

Pharma companies are unsure of the extent of the commercialization of phytotherapic drugs in Brazil, according to research by Pharmaceutical Technology, reported by Brazil Pharma News.

Dozens of studies link Brazil’s herbal medicines to successful treatments and cures of various ailment including cancer-fighting medicines and anti-fungals. However, the potential of this market is untapped according to industry sources. Most of the investment has come from the cosmetics market and not the pharma industry, as the growth of phytotherapic drugs has not been officially regulated by the Brazilian Health Surveillance Agency (ANVISA).

Barriers to production

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >